The SERENITY At-Home Phase 3 trial is a double-blind, placebo-controlled study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar ...

Pemvidutide is the only drug currently granted Fast Track Designation in AUD ...

Despite accumulating evidence that cardiovascular disease risk increases during the early stages of bipolar disorder, few ...

Cardiovascular disease is the leading cause of premature deaths in patients with bipolar disorder worldwide. In a novel study ...

Philadelphia, August 19, 2025 – Cardiovascular disease is the leading cause of premature deaths in patients with bipolar disorder worldwide. In a ...

Cardiovascular disease is the leading cause of premature deaths in patients with bipolar disorder worldwide. In a novel study ...

Each organ in the human body contains different types of cells arranged in specific ways.These arrangements aid protein interactions, which drive ...

Selected amongst global academic institutions to conduct a pivotal trial for heavy menstrual bleedingDallas, TX, Aug. 19, ...

Introduction The global albumin market is experiencing consistent expansion, driven by its extensive uses in the pharmaceutical, clinical diagn ...